找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Ciclosporin in Autoimmune Diseases; 1st International Sy Rosemarie Schindler Conference proceedings 1985 Sandoz Ltd, Basle and Springer-Ver

[复制链接]
楼主: fumble
发表于 2025-3-27 00:49:51 | 显示全部楼层
https://doi.org/10.1007/978-3-322-80961-2keletal muscle due to interference with neuromuscular transmission by antibodies to acetylcholine receptors (AChR). Circulating polyclonal anti-AChR antibodies can be demonstrated in nearly 90% of patients with generalized MG [5].
发表于 2025-3-27 03:39:55 | 显示全部楼层
Einleitung: Regieren mit der Mediation,d in the presence of a characteristic skin rash. Cardiac involvement may occur, and certain cases of idiopathic cardiomyopathy without skeletal muscle disease may constitute a separate entity within the group of immunologically mediated myopathies.
发表于 2025-3-27 07:37:33 | 显示全部楼层
https://doi.org/10.1007/978-3-642-70607-3autoimmune disease; diseases; research
发表于 2025-3-27 12:53:05 | 显示全部楼层
978-3-642-70609-7Sandoz Ltd, Basle and Springer-Verlag Berlin Heidelberg 1985
发表于 2025-3-27 15:28:58 | 显示全部楼层
Studien zur politischen GesellschaftMyasthenia gravis (MG) is a humorally mediated autoimmune disease. Circulating autoantibodies (ab) against the postsynaptic acetylcholine receptor (ACHR) are responsible for the postsynaptic transmission failure which is the cause of the abnormal weakness and fatigability of the skeletal muscles in myasthenics [16].
发表于 2025-3-27 19:32:35 | 显示全部楼层
Ciclosporin (CyA) in Myasthenia GravisMyasthenia gravis (MG) is a humorally mediated autoimmune disease. Circulating autoantibodies (ab) against the postsynaptic acetylcholine receptor (ACHR) are responsible for the postsynaptic transmission failure which is the cause of the abnormal weakness and fatigability of the skeletal muscles in myasthenics [16].
发表于 2025-3-28 01:36:29 | 显示全部楼层
Preface to CyA Proceedingssms of action it was self-evident that the new substance should be tested also in the wide field of autoimmune diseases. With this volume an attempt has been made to provide full information to the scientific community about the status of ciclosporin as a possible treatment in these indications.
发表于 2025-3-28 02:52:40 | 显示全部楼层
发表于 2025-3-28 09:49:40 | 显示全部楼层
发表于 2025-3-28 11:13:09 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 吾爱论文网 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
QQ|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-8-17 14:16
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表